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ARTICLE
Aβ34 is a BACE1-derived degradation intermediate
associated with amyloid clearance and Alzheimer’s
disease progression
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The beta-site APP cleaving enzyme 1 (BACE1) is known primarily for its initial cleavage of the
amyloid precursor protein (APP), which ultimately leads to the generation of Aβ peptides.
Here, we provide evidence that altered BACE1 levels and activity impact the degradation of
Aβ40 and Aβ42 into a common Aβ34 intermediate. Using human cerebrospinal ﬂuid (CSF)
samples from the Amsterdam Dementia Cohort, we show that Aβ34 is elevated in individuals
with mild cognitive impairment who later progressed to dementia. Furthermore, Aβ34 levels
correlate with the overall Aβ clearance rates in amyloid positive individuals. Using CSF
samples from the PREVENT-AD cohort (cognitively normal individuals at risk for Alzheimer’s
disease), we further demonstrate that the Aβ34/Aβ42 ratio, representing Aβ degradation
and cortical deposition, associates with pre-clinical markers of neurodegeneration. We pro-
pose that Aβ34 represents a marker of amyloid clearance and may be helpful for the char-
acterization of Aβ turnover in clinical samples.
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The pathogenesis of Alzheimer’s disease (AD) is character-ized by amyloid-β (Aβ) plaque formation in the brain1,2.Sequential cleavage of the amyloid precursor protein (APP)
by β-secretase (BACE1) and the γ-secretase complex results in the
generation of Aβ species of varying lengths, e.g., Aβ38, Aβ40, and
Aβ423,4,5,6. More neurotoxic than Aβ38 or Aβ40, the Aβ42
peptide is prone to form oligomers (i.e., precursor to larger
ﬁbrils), which are thought to contribute to plaque formation and
cognitive decline7.
To block the ﬁrst step of amyloid production, the pharma-
ceutical industry has focused on inhibitors of BACE1 as a ther-
apeutic strategy for AD. However, BACE1 inhibitors have failed
in clinical trials due to side effects, possible toxicity, or the
absence of beneﬁcial cognitive outcomes8. The lack of success
may also relate to the timing of administration, since treatments
in the symptomatic stage might be too late.
BACE1 levels are elevated in the neocortex of AD patients9–11.
Perhaps as a pathological response to ﬁbrillar Aβ, the accumu-
lation of BACE1 in the vicinity of amyloid plaques can enhance
local Aβ generation12–16. However, excess BACE1 activity can
also lead to (i) alternative APP processing at the β’-site, gen-
erating metabolically labile Aβ11-X peptides17, or (ii) Aβ degra-
dation, by catalyzing the C-terminal truncation of Aβ40 and
Aβ42 into non-amyloidogenic Aβ3418–21. In human and canine
in vivo studies, cerebrospinal ﬂuid (CSF) levels of Aβ34 decline
with pharmacological BACE1 inhibition, most likely due to an
interruption of the BACE1-mediated degradation of Aβ40 and
Aβ4222,23. However, the amyloidolytic roles of BACE1 in Aβ
metabolism are currently not well deﬁned, either in health (i.e.,
physiological homeostasis) or disease (i.e., AD pathogenesis).
The pathological cascade of sporadic AD appears to be trig-
gered by impaired Aβ degradation and clearance24. Aβ clearance
from the brain can occur by several mechanisms including
interstitial ﬂuid drainage, cellular uptake, and passive
elimination25,26. Enzymatic degradation generates speciﬁc pat-
terns of soluble Aβ peptides in the CSF27, as mediated by Aβ-
degrading enzymes (ADEs), which include metalloprotease family
members such as endothelin-converting enzyme (ECE), insulin-
degrading enzyme (IDE), and neprilysin (NEP)28. Results
obtained with 18O-labeling mass spectrometry demonstrated that
the Aβ peptide pattern in CSF is not generated by proteolytic
activities in CSF itself—except in the acute phase of a bacterial
meningitis29—but Aβ fragments are likely generated prior to
entering the CSF.
The normal clearance rate for Aβ40 or Aβ42 in human CSF is
estimated to be ~8% per hour30, but clearance is impaired by
approximately 30% in AD patients24. Aβ stable isotope labeling
kinetics (SILK) studies found that production and clearance of
soluble Aβ isoforms are similar for Aβ38 and Aβ40, but Aβ42
turnover is altered with increasing age and amyloidosis31.
Since we have previously shown that Aβ34 is a common
intermediate in the enzymatic processing of two distinct Aβ
degradation pathways6, the present study examines the levels and
metabolism of Aβ34 in the brains of BACE1-deﬁcient mice, in
brain and CSF of rats treated with a BACE1-speciﬁc inhibitor, a
cultured human neuronal cell line (SH-SY5Y), and CSF samples
from individuals at various clinical stages of AD. To accomplish
this, we utilize a custom, ultra-sensitive Meso Scale Discovery
(MSD) electrochemiluminescence assay, using a monoclonal neo-
epitope antibody that binds speciﬁcally to the C-terminus of
Aβ34 with nanomolar afﬁnity. Our results show that cerebral
BACE1 levels are limiting for Aβ34 generation in vivo. Speciﬁ-
cally, in well-characterized clinical groups, CSF levels of Aβ34 are
notably elevated in individuals with mild cognitive impairment
(MCI) who later progressed to AD dementia. Compared with the
classical Aβ40/Aβ42 ratio (i.e., marker of amyloid deposition in
clinical practice), the Aβ34/Aβ42 ratio improves our ability to
distinguish between individuals with MCI who later converted to
AD from those who did not. Among cognitively normal indivi-
duals at risk for AD, an elevated CSF-Aβ34/Aβ42 ratio is detected
together with current biomarkers of pre-clinical AD, such as
elevated CSF levels of total-tau (t-tau) and phosphorylated (P181)-
tau. Furthermore, the overall Aβ clearance rates positively cor-
relate with CSF-Aβ34 levels in amyloid-positive (Aβ+)
individuals.
While the interesting Aβ34 biology of this article directly
impacts the design of future studies looking at Aβ turnover and
clinical studies involving BACE inhibitors, we anticipate that
combining markers of amyloid clearance (Aβ34 measurements)
and deposition (well-established Aβ42 measurements in CSF)
may provide a more complete biomarker panel to assess AD
samples (i.e., early-stage biochemical changes vs. late-stage pla-
que/tangle pathology). Future studies are needed to validate
whether an increased CSF-Aβ34/Aβ42 ratio may provide an
opportunity for earlier intervention strategies.
Results
Cerebral Aβ34 is decreased in BACE1-deﬁcient mice. Given
that BACE1 can directly cleave longer Aβ species between Leu34
and Met35 in vitro19,20 (Supplementary Fig. 1), we hypothesized
that Aβ degradation would be affected by altered BACE1
expression levels in vivo. To test this, we analyzed endogenous
cerebral BACE1, APP, and Aβ levels from BACE1−/− and
BACE1+/− mice, as well as their wild-type (BACE1+/+) lit-
termates (Fig. 1a–g). In agreement with previously published
results32,33, BACE1 protein levels in the brain of BACE1+/−
mice were approximately half that of wild-type mice, as analyzed
by western blot (Fig. 1a, b). Furthermore, BACE1−/− mice had
signiﬁcantly elevated levels of cerebral APP and/or solu-
ble APP (sAPP) compared with their BACE1+/− and wild-type
littermates, whereas there was no signiﬁcant difference between
BACE1+/− and wild-type animals (Fig. 1a, c). Notably, the
former is possibly due to increased levels of full-length APP34.
We next measured endogenous levels of Aβ34, Aβ38, Aβ40,
and Aβ42 peptides in the brains of these same mice using a
custom 4-plex MSD multiplexing assay (Supplementary Methods,
Supplementary Figs. 2, 3). In agreement with previous ﬁndings in
mice and rats32,35,36, Aβ38, Aβ40, and Aβ42 were signiﬁcantly
decreased in BACE1−/− mouse brains, whereas their levels did
not differ signiﬁcantly between BACE1+/− and wild-type
littermates (Fig. 1e–g). As expected for a fragment generated
by BACE1 activity, cerebral Aβ34 levels were decreased in
BACE1−/− mice compared with BACE1+/− (Fig. 1d). Notably,
Aβ34 levels were also signiﬁcantly lower in BACE1+/− mice
compared with wild-type littermates. Apparently, the cerebral
amyloidogenic processing of endogenous APP by BACE1 is not
impaired by a 50% decreased enzyme availability, as it is
indistinguishable in heterozygous knockouts and wild-type
littermates (Fig. 1e–g). Furthermore, the Aβ34/Aβ38, Aβ34/
Aβ40, and Aβ34/Aβ42 ratios revealed a step-wise decrease with
decreasing BACE1 levels (Fig. 1h–j). These ﬁndings support the
concept that cerebral BACE1 levels are limiting for its
amyloidolytic activity in vivo relying on conversion of the longer
Aβ species to Aβ34, whereas BACE1 levels are not limiting for
APP cleavage resulting in Aβ38, Aβ40, and Aβ42.
BACE1 inhibition lowers rat CSF and brain Aβ34 levels. To
independently assess whether the above ﬁndings hold true for the
pharmacological intervention with BACE1 activity, wild-type rats
were treated with the BACE1-speciﬁc inhibitor MK-893137. The
inhibitor had no effect on cerebral APP and/or sAPP levels
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(Fig. 2a, b). Cerebral Aβ34 levels were signiﬁcantly decreased in
rats treated with concentrations of 1 and 20mg/kg (Fig. 2c). In
contrast, cerebral Aβ40 and Aβ42 levels were only decreased in
the 20 mg/kg but not the 1 mg/kg cohort (Fig. 2d, e). Conse-
quently, the ratios Aβ34/Aβ40 and Aβ34/Aβ42 were signiﬁcantly
decreased at 1 and 20 mg/kg (Fig. 2f, g). In agreement with our
ﬁndings in BACE1+/− mice, these results indicate that cerebral
Aβ34 levels are more sensitive to changes in BACE1 activity than
the longer Aβ species.
We next measured CSF levels of Aβ34, Aβ38, Aβ40, and Aβ42.
CSF-Aβ34 was signiﬁcantly decreased in the cohorts treated with
1 and 20 mg/kg (Fig. 2h), however, there was no change for Aβ38,
Aβ40, and Aβ42 (Fig. 2i–k). Furthermore, the ratios Aβ34/Aβ38,
Aβ34/Aβ40, and Aβ34/Aβ42 in CSF were signiﬁcantly decreased
in the animals treated with 1 and 20 mg/kg (Fig. 2l–n). Overall,
the results of these experiments demonstrate that the pharma-
cological inhibition of BACE1 differentially affects the amyloido-
genic and the amyloidolytic activities of the enzyme in vivo.
Importantly, the latter seems more sensitive than the former to
the amount (Fig. 1) and activity (Fig. 2) of BACE1.
Aβ34 is an Aβ degradation intermediate. Previous studies
showed that APP and BACE1 expression can change the quantity
c
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of Aβ produced33,38. Therefore, we tested whether Aβ34 levels
would be affected by a surplus of either substrate or enzyme in a
human neuronal cell type. Using human neuroblastoma (SH-
SY5Y) cells stably overexpressing APP or BACE1 (Fig. 3a), we
measured secreted levels of Aβ34, Aβ38, Aβ40, and Aβ42 in the
supernatants using the ultra-sensitive 4-plex assay, whereas
sAPPβ and sAPPtotal were detected by western blot (Fig. 3a–h).
Overexpression of APP mildly increased Aβ34 levels (not statis-
tically different from empty plasmid (Mock)-transfected cells,
p= 0.06) and signiﬁcantly elevated sAPPβ, sAPPtotal, Aβ38, Aβ40,
and Aβ42, as compared with Mock-transfected cells (Fig. 3b–h).
Conversely, in BACE1-overexpressing cells, Aβ34 levels were
signiﬁcantly elevated approximately threefold compared with
APP-overexpressing conditions, whereas Aβ38, Aβ40, and Aβ42
levels showed only a mild trend toward elevation compared with
the control (Fig. 3e–h). Furthermore, more APP was shed from
either of these cell lines (Fig. 3c, d). Note that the apparent
molecular weights of endogenous APP and sAPPs are slightly
higher than those from APP695-transfected cells (Fig. 3a, b),
which is likely due to the fact that undifferentiated SH-SY5Y cells
express not only APP695 but also splice variants with KPI- and
OX-2 domains39,40. Overall, we conclude that a surplus of either
ca b
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substrate or enzyme affects APP processing differentially in the
human neuronal cell line, resulting in (i) increased Aβ38, Aβ40,
and Aβ42 release from APP-overexpressing cells, or (ii) an
enhanced degradation of all longer Aβ forms into Aβ34 in
BACE1-overexpressing cells.
To investigate whether BACE1 inhibition differentially affects
the Aβ proﬁles, SH-SY5Y cells overexpressing APP or BACE1
were treated with MK-893137 at approximately 20-fold of its
published IC50 (i.e., [MK-8931]= 100 nM, Fig. 4, Supplementary
Fig. 4). Conditioned medium from APP-overexpressing SH-SY5Y
cells showed signiﬁcantly decreased levels of sAPPβ, Aβ34, Aβ38,
Aβ40, and Aβ42 in the presence of MK-8931 (Fig. 4a–d,
Supplementary Fig. 4a–c). Furthermore, a dose-inhibition curve
for MK-8931 was performed and sAPPβ (western blot), Aβ34
(MSD 1-plex), and Aβ40 (MSD 1-plex) were measured
(Supplementary Fig. 4d–f). In APP-overexpressing SH-SY5Y
cells, MK-8931 dose-dependently decreased sAPPβ (pIC50=
10.7 ± 0.3 (s.e.m.)), Aβ34 (pIC50= 14.1 ± 0.6), and Aβ40 levels
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Aβ38 (f), Aβ40 (g), and Aβ42 (h). Data were collected from four independent experiments. Bars and error bars indicate mean ± s.e.m. c–h Data were
analyzed with one-way ANOVAs and Tukey’s post-hoc tests were performed for pairwise comparisons; selected comparisons are highlighted ***p < 0.001,
*p < 0.05, ns= nonsigniﬁcant p > 0.05. c sAPPβ, F(2, 9)= 131.2, p < 0.0001, d sAPPtotal, F(2, 9)= 190.3, p < 0.0001, e Aβ34, F(2, 9)= 70.04, p < 0.0001, f
Aβ38, F(2, 9)= 149.0, p < 0.0001, g Aβ40, F(2, 9)= 89.96, p < 0.0001, h Aβ42, F(2, 9)= 113.6, p < 0.0001
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(pIC50= 11.3 ± 0.7) (Supplementary Fig. 4d–f). In contrast, in
conditioned medium from BACE1-overexpressing SH-SY5Y cells,
only the levels of sAPPβ and Aβ34 were signiﬁcantly decreased in
the presence of the inhibitor (Fig. 4e, f, Supplementary Fig. 4g, h),
whereas Aβ38 and Aβ40 were signiﬁcantly increased and Aβ42
levels showed a trend for being elevated, p= 0.1 (Supplementary
Fig. 4i, Fig. 4g, h). In BACE1-overexpressing SH-SY5Y cells, MK-
8931 only dose-dependently decreased sAPPβ (pIC50= 8.3 ± 0.3)
and Aβ34 levels (pIC50= 7.3 ± 0.2) (Supplementary Fig. 4j, l).
Interestingly, Aβ40 levels were decreased at high inhibitor
concentrations (p[MK-8931] >−6), elevated at intermediate
concentrations (−10 < p[MK-8931] <−6) and unchanged at
low concentrations (−10 > p[MK-8931]) (Supplementary Fig. 4k).
Ultimately, these results show that the response to pharmacolo-
gical BACE1 inhibition depends on the relative abundances of
BACE1 and its substrate APP. Notably, inhibition with
insufﬁcient amounts of compound at high levels of BACE1 could
result in undesired elevated Aβ40 and Aβ42 levels. However,
BACE1 inhibitor doses used in vivo can effectively reduce the
levels of longer Aβ species37.
ADEs include the metalloproteases, a large group of proteases
that likely cleave Aβ peptide substrates28. In general, ADE-derived
fragments are short, soluble, and not prone to aggregate. To
investigate how Aβ34, Aβ38, Aβ40, and Aβ42 degradation is
affected by metalloproteases, we treated APP- or BACE1-
overexpressing SH-SY5Y cells with the metalloprotease inhibitor
phosphoramidon (PA). Supernatants were analyzed using the 4-
plex MSD assay as before (Fig. 5). In APP-overexpressing cells, PA
treatment signiﬁcantly elevated the levels of all Aβ species
measured (Fig. 5a–d). In the presence of PA, however, Aβ34 was
increased approximately ninefold, whereas the levels of Aβ38,
Aβ40, and Aβ42 were only about two to threefold higher
(Fig. 5a–d). In agreement with previously published data21, these
ﬁndings imply that Aβ34 is more sensitive to metalloprotease-
mediated degradation compared with the longer species tested. In
BACE1-overexpressing cells, Aβ34 levels were increased by about
2.5-fold in the presence of PA, whereas Aβ38, Aβ40, and Aβ42
levels were not signiﬁcantly changed (Fig. 5a–d). Together, these
results suggest that Aβ34 is a stable Aβ degradation intermediate of
the amyloid degradation cascade. Thus, we propose that in the
presence of surplus APP substrate, Aβ38, Aβ40, and Aβ42 are
degraded by both metalloproteases and the BACE1-mediated Aβ34
pathway (Fig. 5e). Conversely, in the presence of surplus BACE1
enzyme, longer forms of Aβ are predominantly degraded by
BACE1, yielding Aβ34 as a metastable cleavage product (Fig. 5e).
CSF-Aβ34 levels are associated with AD progression. To
explore the associations between Aβ34 and putative changes in
BACE1 expression observed in AD9–11, we analyzed Aβ34 in 98
human CSF samples from the Amsterdam Dementia Cohort.
Samples were collected from 22 people with subjective cognitive
complaints (SC), 17 with MCI that remained stable, 27 with MCI
that later progressed to AD dementia (i.e., MCI converters), and
32 AD patients. Using our MSD assay, we found signiﬁcantly
elevated Aβ34 levels in the CSF of MCI converters when com-
pared with SC or MCI stable (Fig. 6a). Furthermore, the levels in
MCI converters showed a trend for being elevated compared with
AD patients (the greater variability is likely due to a larger het-
erogeneity in this group). CSF-Aβ34 levels from all groups did
not associate with age, the genetic risk allele APOE ε4, or gender
(Supplementary Fig. 5a–c). As expected, there was a decrease in
Aβ42 in AD patients and MCI converters compared with the SC
and MCI stable group (Fig. 6b). These changes are likely due to
the sequestration of Aβ42 into amyloid plaques and indicate that
MCI converters and AD patients are typically Aβ+41. The Aβ34/
Aβ42 ratio is signiﬁcantly elevated in the MCI converter and AD
groups compared with the other groups (Fig. 6c).
To assess whether CSF-Aβ34 could provide important
information during the early stages of AD, we tested whether
Aβ34 could discriminate between MCI converters vs. non-
converters from the Amsterdam Dementia Cohort. Receiver
operating characteristic (ROC) curves of the CSF analytes were
used to determine the accuracy of distinction between the MCI
converters (i.e., prodromal AD) vs. stable patients. The area under
the curve (AUC) for Aβ34 alone was slightly smaller than for
Aβ42 (Fig. 6d). Interestingly, the Aβ34/Aβ42 ratio (AUC= 0.91)
signiﬁcantly improved the diagnostic accuracy compared with the
classical Aβ40/Aβ42 ratio (AUC= 0.82) (Fig. 6e). An optimal
cut-off analysis42 yielded the best cut-off for an Aβ34/Aβ42 ratio
>0.245, where sensitivity was 81.48% and speciﬁcity 82.35%
(Supplementary Fig. 5d). The improved diagnostic accuracy of
the Aβ34/Aβ42 ratio seemed speciﬁc for the distinction between
MCI converters and stables. Similar AUCs ranging from 0.93 to
0.98 were obtained for Aβ42, Aβ40/Aβ42, and Aβ34/Aβ42 for the
distinction between the SC and MCI converters or the SC and AD
populations respectively (Supplementary Fig. 5e, f). For the
distinction between MCI converters and stable patients, p-tau and
t-tau yielded AUCs of 0.93 and 0.94, respectively (Fig. 6f). To
assess how Aβ34/Aβ42 compares with the core AD biomarkers43,
we calculated the ratio between the MCI converter and MCI
stable groups (Fig. 6g). Aβ34/Aβ42 ranked third after the core
markers, i.e., total- and phosphorylated-tau but before Aβ40/
Aβ42 and Aβ42 (Fig. 6g). Overall, these results suggest that using
Aβ34, an indicator for Aβ degradation in combination with Aβ42,
a core biomarker for Aβ deposition, can improve the accuracy of
prediction compared with Aβ40/Aβ42 regarding MCI patients
who will convert to dementia vs. non-converters. The Aβ34/Aβ42
ratio could complement but not supplant existing biomarkers,
such as CSF levels of total- and phosphorylated-tau. This ﬁnding
suggests that, at certain stages of Aβ34 elevation in the CSF, the
combination of this marker with reduced Aβ42 may indicate a
failure in the clearance pathway associated with AD progression.
To test whether changes in the Aβ34/Aβ42 ratio are already
detectable in earlier, pre-symptomatic AD, likely even before
signs of neuronal injury become evident, we analyzed another 94
human CSF samples from cognitively normal, at-risk individuals
from the PREVENT-AD cohort44. Individuals enrolled in this
study have no diagnosable cognitive dysfunction and are in good
general health, but they have a family history of a parent or
multiple siblings affected with AD dementia45–47. At enrollment,
these individuals were on average 10.2 years younger than the age
of dementia onset for their earliest-affected relative. Consistent
with our earlier Amsterdam Dementia Cohort ﬁndings, CSF-
Aβ34 levels in the PREVENT-AD samples were not associated
with age, APOE ε4, or gender (Supplementary Fig. 6a–c). We then
tested whether an increased Aβ34/Aβ42 ratio (optimal cut-off
Aβ34/Aβ42 > 0.245; Fig. 6e) could also be observed in cognitively
normal individuals from the PREVENT-AD cohort. We identi-
ﬁed 17 out of 94 individuals (18.09%) with Aβ34/Aβ42 ratios that
were above our estimated cut-off.
According to current views, the asymptomatic phase of AD is
characterized by a sequential appearance of abnormalities,
starting with increased cortical Aβ deposition (stage 1), leading
to additional signs of neurodegeneration (stage 2; no abnormal-
ities are seen in stage 0)48. Figure 7a depicts the Aβ42 and t-tau
distribution of the PREVENT-AD samples from individuals at
different stages of pre-symptomatic AD, with most individuals
remaining in the stage 0 group. The horizontal and vertical dotted
lines and shaded areas represent Aβ4241 and t-tau cut-off
values49,50 and their inter-assay variances51 (Fig. 7a). The
biomarker assessments (validated CSF-Aβ42 cut-off values
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including the inter-assay variances41,51) indicated that 15
PREVENT-AD participants are likely candidates having pre-
clinical AD at stages 1 and 2 (Fig. 7a). Out of these, 11 presented
with Aβ34/Aβ42 ratios above our cut-off (11/15= 73.33%)
(Fig. 7a). In addition, 6 out of 73 (8.22%) individuals at stage 0
also showed an elevated Aβ34/Aβ42 ratio. Individuals with
elevated Aβ34/Aβ42 were not signiﬁcantly older (Fig. 7b), but
they exhibited signiﬁcantly increased Cardiovascular Risk Factors,
Aging, and Incidence of Dementia scores (CAIDE; Fig. 7c), and
signiﬁcantly increased CSF levels of total- and phosphorylated-
tau (t-tau, p-tau; Fig. 7d, e).
CSF-Aβ34 correlates with Aβ clearance in Aβ+ individuals. In
MCI and sporadic AD brain tissue, the levels and enzymatic
activity of BACE1 are increased9–11 and localized to the sur-
roundings of amyloid deposits12–15. Above, we presented evi-
dence that Aβ34 (an amyloidolytic product of BACE1) is
associated with BACE1-mediated Aβ clearance and is elevated in
MCI converters, who show evidence of amyloid plaques (based
on their CSF-Aβ42 levels41). Thus, we analyzed the CSF con-
centrations of Aβ34, Aβ38, Aβ40, and Aβ42 in Aβ+ and amyloid-
negative (Aβ–) individuals (10 individuals per group; Fig. 8),
whose Aβ turnover was previously assessed by SILKTM 31.
SILKTM data of these 20 individuals were previously reported31
and we correlated our results with the published data. The frac-
tional turnover rate (FTR) or true fractional clearance rate31,
which is associated with the irreversible loss of Aβ38, Aβ40,
and Aβ4252, showed a signiﬁcant positive correlation with the
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CSF-Aβ34 concentrations only in Aβ+ individuals (Fig. 8a–c).
Moreover, the CSF concentrations of Aβ38, Aβ40, and
Aβ42 showed no signiﬁcant correlation with Aβ38, Aβ40, or
Aβ42 FTRs in our dataset (Fig. 8d–l). Interestingly, the ratio
Aβ34/Aβ42 correlated with all three FTRs in Aβ– individuals,
whereas the other ratios showed no correlation (Supplementary
Fig. 7a–i). Overall, the correlation between Aβ34 and the clear-
ance of the longer Aβ species is consistent with our results from
rodent brains and SH-SY5Y cells, suggesting that elevated BACE1
levels in Aβ+ individuals might shift Aβ38, Aβ40, and Aβ42 into
the Aβ34 degradation pathway. In conclusion, Aβ34 might serve
as a surrogate marker for the overall clearance of Aβ38, Aβ40,
and Aβ42 in Aβ+ and the ratio Aβ34/Aβ42 for the overall
clearance in Aβ– individuals.
Discussion
In the AD ﬁeld, research has traditionally focused on the con-
version of APP into Aβ42 peptides leading to pathological amy-
loid plaque deposition in the brain and cognitive decline during
the clinical progression of the disease. In recent years, however,
emerging literature now identiﬁes amyloid clearance as an
important paradigm to better understand amyloid imbalances in
sporadic AD patients.
BACE1 is thought to play a major role in the pathogenesis of
AD and several inhibitors have been evaluated in clinical trials for
their potential to slow or halt the production of neurotoxic Aβ
peptides8. In order to attenuate disease progression in individuals
with existing amyloid plaques, Aβ production would need to be
inhibited by at least 95% since deposition is expected to be fast in
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Aβ+ individuals, even at lowered rates of newly produced
Aβ53,54. Recently, current treatment approaches have been chal-
lenged based upon reports of disappointing results and adverse
effects from BACE inhibitor trials (press release, 25 October 2018,
Is there a role for BACE inhibition in Alzheimer’s treatment?,
Clinical Trials on Alzheimer’s Disease (CTAD) conference).
BACE1 levels are increased in the AD brain9–11, and this could
potentially result in increased Aβ production. However, a ~50%
reduction in cerebral BACE1 (as reported in BACE1+/− mice
and rats) does not alter Aβ38, Aβ40, and Aβ42 levels, suggesting
that half the usual amount of BACE1 is sufﬁcient to fully process
endogenous APP32,33,35,36. Furthermore, increased enzyme levels
do not lead to an increased amyloid load in the brains of mice
overexpressing human BACE155.
We found that cerebral Aβ34 levels were decreased by about
30% in BACE1+/− mice and by about 40% in wild-type rats, 1 h
after intravenous injection of 1 mg/kg MK-8931 (with longer Aβ
species unaltered). In the CSF of these MK-8931-treated rats,
Aβ34 was the only Aβ species that was signiﬁcantly decreased in
the 1 and 20 mg/kg groups. However, since we administered the
inhibitor intravenously, the greatest reduction in Aβ was likely
achieved much earlier than in the original study, where rats
received the compound orally and Aβ40 was signiﬁcantly reduced
in CSF and cortex at 1 and 3 h37. Due to the different routes of
administration, our data cannot be directly compared with this
study37. In contrast to the initial APP cleavage, BACE1 is a
limiting factor for the amyloidolytic cleavage of longer Aβ species
into Aβ34. Furthermore, our data imply that cerebral BACE1
possesses Aβ-degrading properties in vivo, as consistent with an
earlier hypothesis based on in vitro studies19–21. The dichotomy
between the amyloidogenic and amyloidolytic roles of BACE1
becomes more evident in experimental systems with elevated
BACE1 levels. In the present study, for example, we found that an
excess of APP favors amyloidogenic Aβ peptide production, but
an excess of BACE1 results in increased Aβ degradation to Aβ34.
Our characterization of the BACE1-mediated Aβ34 pathway is
consistent with previous ﬁndings that cerebral BACE1 is not
limiting for Aβ production32,33,35,36, observations that until now
had remained unexplained due to our lack of understanding of
amyloidolytic BACE1 activity.
As BACE1-derived Aβ34 can be further degraded by PA-
sensitive metalloproteases21, it may be classiﬁed as a metastable
intermediate in the degradation cascade of amyloidogenic pep-
tides. The current ﬁndings show that this process is regulated by
BACE1 expression such that when BACE1 may become limiting
(i.e., when APP is overexpressed), amyloidogenic Aβ peptides are
enzymatically degraded by both metalloproteases and BACE1.
However, when BACE1 is present in sufﬁcient or excess amounts
(i.e., when overexpressed), the Aβ34 pathway is favored. As
BACE1 is strongly expressed in neurons, particularly at sites of
Aβ production in the brain14,15, longer Aβ peptides may be
favorably converted into non-toxic Aβ34 at these sites. It is likely
that Aβ34 might have a speciﬁc biological function and anti-
apoptotic actions of this fragment on cultured human cells have
been described21, however, a more thorough characterization is
needed in order to determine its physiological role.
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Site-speciﬁc mutations in APP were found in rare cases of
familial early-onset AD (FEOAD) and processing at the β-
cleavage site of APP could be causally linked to increased and
decreased risk of AD. For example, β-cleavage of APP carrying
the Swedish mutation (KM670/671NL) is increased and causes
FEOAD56. In contrast, the Icelandic mutation (A673T) protects
against AD57, primarily by reducing the β-cleavage of APP,
as well as modulating Aβ aggregation58. In light of our ﬁndings, it
is plausible that the Icelandic mutation results in reduced Aβ
generation, whereas BACE1-mediated Aβ degradation still
occurs. Although inhibition of BACE1-mediated cleavage of APP
remains an attractive therapeutic approach in AD, it appears that
reducing BACE1-mediated generation of pathogenic Aβ peptides
alone will not be sufﬁcient to stop plaque growth53,54. Further-
more, BACE1 inhibition is likely to affect amyloidolytic cleavage
of longer Aβ species into smaller, non-amyloidogenic Aβ34. For
this reason, we tested for clearance effects in human CSF and,
notably, we found elevated baseline levels of Aβ34 in MCI
patients who later progressed to AD. Aβ34 can be detected in
human plasma samples59, therefore, it would be interesting to test
whether its levels in CSF and plasma correlate or whether MCI
converters show elevated amounts of plasma-Aβ34. By combining
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Fig. 8 Association between CSF-Aβ34 and Aβ clearance rates. Analysis of Aβ34, Aβ38, Aβ40, and Aβ42 in human CSF with ultra-sensitive assays (Meso
Scale Discovery (MSD)). Aβ38, Aβ40, and Aβ42 clearance (fractional turnover rate, FTR) was previously measured using stable isotope labeling kinetic
(SILK)31. Samples were from n= 10 Aβ+ and n= 10 Aβ– individuals. Scatterplots of CSF-Aβ34 (a–c), Aβ38 (d–f), Aβ40 (g–i), or Aβ42 (j–l) with Aβ38 FTR
(a, d, g, j), Aβ40 FTR (b, e, h, k), or Aβ42 FTR (c, f, i, l). Pearson correlation coefﬁcients (r) were computed to assess the relationship between the
variables. The Bonferroni adjusted p-values are: **p < 0.003, *p < 0.016, ns= nonsigniﬁcant p > 0.0125
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an indicator for Aβ degradation (i.e., Aβ34) and a biomarker for
Aβ deposition (i.e., Aβ42), we found that the Aβ34/Aβ42 ratio
signiﬁcantly improved the diagnostic accuracy to distinguish
between prodromal AD and stable MCI compared with the
classical Aβ40/Aβ42 ratio. However, elevated CSF levels of p-tau
and t-tau showed the best distinction between the two MCI
groups. An elevated Aβ34/Aβ42 ratio in the prodromal stage of
AD could indicate that, at early stages of Aβ plaque formation
(i.e., decreased CSF-Aβ42 levels41), the increased levels and
amyloidolytic activity of BACE1 elicit a defense reaction (i.e.,
increased generation of Aβ34 to facilitate amyloid clearance).
Although BACE1 levels are elevated around ﬁbrillar Aβ12–15, the
ﬁbrillar conformation is resistant to BACE1 cleavage because of
its unique structure60 (under the condition of their co-presence in
a cellular compartment with a low pH). Aβ42 ﬁbrils are stabilized
by hydrophobic clusters in such a way that they do not grant
BACE1 access to the Aβ34 cleavage site60. Furthermore, since
only Aβ42 turnover (and not Aβ38 or Aβ40) is altered when
amyloidosis has started31, the surplus of Aβ34 could be mainly
derived from Aβ42 since its conformation is different from Aβ38
and Aβ40. We speculate that intracellular Aβ42 can adopt a
conformation that is favorable for ﬁbril formation, which makes it
especially susceptible to BACE1-mediated degradation at the
Aβ34 cleavage site.
We hypothesized that the Aβ34/Aβ42 ratio might be poten-
tially useful to monitor pre-symptomatic AD, as changes in the
classical biomarkers of AD pathogenesis can already be observed
before cognitive symptoms appear48. In human samples from the
PREVENT-AD cohort (i.e., at-risk individuals without current
cognitive impairment), we found that the Aβ34/Aβ42 ratio was
elevated, especially in individuals whose biomarker assessment
classiﬁed them in stages 1 and 2 (signs of cortical Aβ deposition).
Overall, few individuals in PREVENT-AD showed reduced CSF-
Aβ42 ( ≤ 647 pg/mL41). In families with autosomal-dominant
AD, reduced CSF-Aβ42 and increased tau in asymptomatic
mutation carriers were already detected 10–20 years before the
estimated age of onset61. At present, members of the PREVENT-
AD cohort tend to be several years younger compared with the
onset of dementia in their affected relative(s) and, in contrast to
mutation carriers, they probably vary substantially in their degree
of progression of pre-symptomatic AD. Interestingly, we identi-
ﬁed individuals in stage 0 with an elevated Aβ34/Aβ42 ratio.
However, our data are cross-sectional and should not be inter-
preted as representing change over chronological ageing. There-
fore, it will be crucial to follow the longitudinal trajectory of Aβ34
in these individuals, in combination with classical CSF measures,
since we expect that these biomarker changes are closely related
to aging, as previously seen in cognitively normal middle-aged
volunteers62.
Consistent with the concept of amyloid clearance and deposi-
tion mechanisms indicating failed clearance in pre-symptomatic
stages of AD, we ﬁnd that the Aβ34 levels in CSF correlate with
the overall clearance rates of Aβ38, Aβ40, and Aβ42 in Aβ+ but
not Aβ– individuals. In contrast, the CSF Aβ34/Aβ42 ratios
correlate with the overall clearance rates of Aβ38, Aβ40, and
Aβ42 in Aβ– but not Aβ+ individuals. Since inter-individual
variances in Aβ clearance rates are affected by various factors
including age, genetics, or pathological processes24,31,52,63, it is
rather unlikely that the levels of an individual protein, such as
BACE1, could determine the overall Aβ clearance from the brain.
However, our ﬁndings suggest that under pathological conditions,
elevated BACE1 levels in the brain direct a large proportion of
Aβ38, Aβ40, and Aβ42 into BACE1-mediated Aβ clearance via
the Aβ34 degradation pathway. Given this, Aβ34 might be used as
a marker for the overall clearance of these peptides in Aβ+
individuals. We speculate that under non-pathological conditions,
a special relationship exists between Aβ34 and Aβ42, which might
explain the correlation of their ratio with the overall Aβ clearance.
Once Aβ42 gets deposited in plaques, the correlation with
clearance is lost, likely due to an altered Aβ42 degradation. Under
these circumstances, Aβ34 alone becomes the predictor of
clearance rates.
In summary, our results show that, in vivo, BACE1 is limiting
for the degradation of longer Aβ peptides into the intermediate
Aβ34. The levels of this amyloidolytic fragment are elevated in the
CSF of prodromal AD patients (i.e., MCI that progresses to AD).
Thus, incorporating Aβ34 as a marker of amyloid clearance with
a marker of amyloid deposition (i.e., Aβ42) might complement
current CSF measures, especially in clinical intervention trials
that aim at a modulation of APP processing (Fig. 9). Ultimately,
the present study proposes that enzymatic processes affecting Aβ
metabolism are altered in early phases of AD and, accordingly,
Aβ34 can be used to monitor Aβ turnover at earlier stages of this
devastating disease.
Methods
Synthetic Aβ peptides. Synthetic peptides Aβ34, Aβ35, Aβ38, Aβ40, and Aβ42
(PSL, Germany) dissolved in formic acid and vacuum dried in a speed-vac
(Thermo) were resuspended (2 mg/mL) in 1% Milli-Q/ammonia water, ultra-
sonicated (10 min 4 °C), diluted to 1 mg/mL with Milli-Q and ultrasonicated again.
Peptide concentrations (ε= 1490M/cm), integrity, and molecular weight were
conﬁrmed by absorption measurements at 280 nm (Synergy H1, BioTek Instru-
ments Inc. plate reader), Coomassie dye stains after performing denaturing poly-
acrylamide gel electrophoresis (SDS-PAGE), and matrix-assisted laser desorption
ionization mass spectrometry (Bruker UltraﬂeXtreme MALDI-TOF/TOF system in
standard reﬂector-positive mode; samples mixed 1:1 with α-cyanocinnamic acid
matrix and applied to ground steel targets using dried-droplet method).
BACE1-mediated Aβ degradation in vitro. BACE1 from Fc puriﬁcation64 10 μg/
mL (a kind gift from Johan Lundkvist, AstraZeneca) was incubated with synthetic
Aβ35, Aβ40, or Aβ42 at 50 μg/mL for 10 min at 37° C in 20 mM (sodium acetate/
HCl, pH4.5), directly mixed 1:1 with α-cyanocinnamic acid matrix, and applied to
ground steel targets using dried-droplet method.
MSD assay. Using the ELISA Conversion Kit from MSD (USA), an
electrochemiluminescence-based assay was developed (neo-epitope speciﬁc Aβ34
and the sulfo-tagged 6E10 (binds to the N-terminus of human Aβ) or the sulfo-
tagged 4G8 for rodent samples (binds to the mid domain of Aβ)). High-bind or
custom-printed 4-plex plates (using our mab34, 4G8 (Biolegend) for pan-Aβ assay,
G2-10 for 1-plex Aβ40 assay, and MSD’s validated mouse monoclonal anti-Aβ38,
anti-Aβ40, as well as anti-Aβ42 antibodies, see MSD Aβ peptide V-PLEX) were
blocked (MSD 5% Blocker A in PBS) for 1 h at 22 °C and washed three times with
PBS-Tween (PBS-T) for 1 min at 22 °C, loaded with SULFO-TAGTM 6E10 or 4G8
detection antibody (diluted to 1× in MSD Diluent 100) and sample or peptide
calibrator (in MSD Diluent 35 or cell culture medium), and incubated for 16 h at
4 °C with shaking at 600 rpm. After three washing steps with PBS-T for 1 min at
22 °C, 150 μL 2× MSD read buffer was added per well. All plates were read using an
MSD QuickPlex SQ 120 Imager and data analyzed using MSD Workbench®
software. Standard curves were ﬁtted using a non-linear four-parameter logistic ﬁt
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Fig. 9 Conceptual model of early changes in AD. Before a clinical diagnosis
of Alzheimer’s disease (AD), decades of Aβ peptide deposition lead to
plaque formation in pre-symptomatic and prodromal stages of the disease.
Incorporating Aβ34 (marker of enzymatic Aβ degradation) with measures
of Aβ42 (marker for cerebral Aβ deposition) could complement current
biomarker assessments and provide additional information about Aβ
turnover
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with 1/y2 weighting. The equation is:
y ¼ b2 þ
b1  b2
1þ xb3
 b4 ð1Þ
y= signal, x= concentration, b2= estimated response at inﬁnite concentration,
b1= estimated response at Zero concentration, b3=mid-range concentration,
b4= slope factor.
In the WORKBENCH® software, lower limit of detection (LLOD) was
determined as the analyte concentration equivalent to the signal that is 2.5×
standard deviations (SD) above the back-ﬁt signal of the blank. Assay performance
(inter-plate, intra-plate coefﬁcient of variation (CV), LLOD, and upper limit of
detection (ULOD)) were assessed using peptide calibrators in MSD diluent 35
(Supplementary Fig. 1e). Spike-and-recovery and linearity-of-dilution assessments
for human CSF samples (compared with calibrators in MSD diluent 35) are given
in Supplementary Table 1.
Western blot analysis. Lithium dodecyl sulfate loading buffer (Invitrogen) with 2-
Mercaptoethanol (ﬁnal concentration 5% (v/v)) was added to samples and the mix
was heated to 70 °C for 10 min. Proteins were separated on 4–12% bis/tris gradient
gels. Novex® Sharp Pre-Stained Protein Standard (Invitrogen) was used. Peptides/
proteins were transferred onto polyvinylidene ﬂuoride membranes (Millipore) by
tank blotting (Bio-Rad) at 4 °C. The primary antibodies, anti-actin C4 dilution
1:4000 (Millipore, Catalog #MAB1501), anti-APP ectodomain 22C11 dilution
1:10,000 (Millipore, Catalog #MAB348), anti-BACE1 D10E5 dilution 1:2000 (Cell
Signaling, Catalog #mAb5606), anti-sAPPβ dilution 1:2000 (IBL, Catalog
#JP18957), and secondary antibodies dilutions 1:10,000 (horseradish peroxidase-
conjugated anti-mouse, anti-rabbit, Promega, Catalog #W4021 and # W4011), were
used. Most important full-size western blots are displayed in Supplementary Fig. 8.
Signals were recorded on ImageQuant LAS 500 or Amersham Imager 600 (GE
Healthcare Life Sciences).
Mouse brain lysates. We complied with all relevant ethical regulations for animal
testing and research. Brains were obtained from BACE1−/− and BACE1+/−
mice, as well as their wild-type littermates65 in accordance with the guidelines of
the Institutional Animal Care and Use Committee at the University of Kiel. Frozen
mouse brains were thawed on ice, weighed and homogenized in 100 mM Tris-HCl,
150 mM NaCl, 2× complete protease inhibitor cocktail (Roche) using gentle-
MACS™ M Tubes/Dissociator at 4 °C (Miltenyi Biotech). Triton X-100 was added
for a ﬁnal concentration of 1% and brain homogenates were lysed for 1 h at 4 °C.
Lysates were centrifuged at 10,621 × g in a microfuge (Eppendorf) at 4 °C for 15
min to remove nuclear fraction. Samples were diluted in the appropriate buffers for
protein determination using bicinchoninic acid assay (BCA assay, Pierce) and MSD
assays.
Pharmacological treatment of rats. We complied with all relevant ethical reg-
ulations for animal testing and research. Experiments were approved by the McGill
Animal Care Ethics Committee. Six to 8 weeks old male Sprague–Dawley rats were
housed at the Douglas Mental Health University Institute animal facility and
treatments were performed in accordance with the guidelines of the Canadian
Council on Animal Care. Rats were intravenously injected with indicated con-
centrations of MK-8931 (Selleckchem) or vehicle (20% Cyclodextrin) and samples
were collected after 1 h of treatment. CSF was collected with the aid of a stereotaxic
instrument to appropriately position the head of the rat and samples stored at
−80 °C. Brain tissue samples were harvested and immediately preserved on dry ice,
later stored at −80 °C. Rat brain lysates were prepared in the same way as mouse
brain lysates.
Plasmids, mutagenesis. Human full-length BACE1 (isoform A) and human full-
length APP (isoform APP695, with an N-terminal Myc tag and a C-terminal FLAG
tag), in the mammalian expression vector pCEP4, Hygro (Invitrogen) were used for
expression. All constructs were veriﬁed by DNA sequencing.
Cell culture and transfection. Human neuroblastoma (SH-SY5Y) cells (DSMZ
No.: ACC 209; DSMZ, Braunschweig/ Germany) were cultured in 50% Dulbecco’s
modiﬁed Eagle’s medium, 50% Hams-F12, 10% fetal bovine serum, 2 mM L-glu-
tamine, 0.5 mM sodium pyruvate, 1× MEM non-essential amino-acid solution in a
humidiﬁed incubator at 37 °C with 5% CO2. Cells were routinely tested for
mycoplasma contamination. SH-SY5Y cells were transfected using TransFectinTM
according to the manufacturer’s instructions (Bio-Rad) and stable clones were
selected using 250 µg/mL Hygromycin B. For experiments, culturing medium
without Hygromycin B was used and conditioned for 16 h. Protease inhibitors,
were dissolved in Dimethyl sulfoxide (DMSO) at a 1000× concentration and
compared with vehicle treatment (DMSO 1:1000). Cells were harvested on ice. Cell
culture supernatants were collected, centrifuged for 10 min at 450 × g in a micro-
centrifuge at 4 °C and used for further analysis. Cells were washed once on ice with
ice-cold PBS++ and lysed in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 20 mM 3-
[(3-cholamidopropyl) dimethyl-ammonio]-1-propanesulfonate (CHAPS), 2×
Complete protease inhibitor (Roche), for 60 min at 4 °C. Cell lysates were
centrifuged for 15 min at 10,621 × g in a microcentrifuge at 4 °C to remove nuclear
fraction.
CSF samples. We complied with all relevant ethical regulations for work with
human participants. The studies were performed in accordance with The Code of
Ethics of the World Medical Association (Declaration of Helsinki). The studies
were approved by the regional ethics committees. Written informed consent was
received from participants prior to inclusion in the studies.
CSF samples for initial assay development were received from the Clinic at
the Division of Psychiatry, Zurich. CSF samples from individuals with SILK
data31 were obtained from the Department of Neurology, Washington
University in St. Louis. CSF samples from individuals with different clinical
diagnoses were received from the Amsterdam Dementia Cohort and the time
interval between CSF collection and assessment of cognition was <24 h66. CSF
samples from cognitively normal individuals at risk for AD (PREVENT-AD
study) were received from the Douglas Mental Health University Institute and
the time interval between CSF collection and assessment of cognition was on
average 5.6 ± 3.9 (SD) months44. The experimentalist was blinded from
diagnosis until completion of measurements. Diagnoses of probable AD67 or
MCI68, were made by consensus of a multidisciplinary team according to
diagnostic criteria. For the Amsterdam Dementia Cohort, patients who
presented with cognitive complaints but were considered as normal after
thorough investigation (i.e., criteria for MCI, dementia or any psychiatric or
neurological results not fulﬁlled) were deﬁned as patients with subjective
cognitive complaints (SC). Subjects were followed annually and MCI to AD
conversion (or MCI that remained stable) was deﬁned based on conversion to
AD within 3 years after the CSF collection, and stable as no conversion occurred
within 3 years. Lumbar punctures after an overnight fast were performed using
the Sprotte 24-gauge atraumatic needle. Samples were aliquoted into propylene
cryotubes and stored at −80 °C. Procedures from the BIOMARK-APD
consortium of the EU Joint Program in Neurodegenerative Disease were used for
sample preparation and measurements69. A summary of samples included in the
study is given in Supplementary Table 2. CSF t-tau, p-tau, and Aβ42 were
measured using INNOTEST ELISA; Fujirebio (formerly Innogenetics).
Statistical analysis. The statistical evaluation was carried out by GraphPad Prism,
SPSS, MedCalc Version 18.2.1, and the indicated statistical tests and algorithms
(analysis of variance (ANOVA), t-test, Pearson correlation, Mann–Whitney U-tests,
Spearman correlations, De Long statistics to compare ROC curves70). The optimal
cut-off (point on the ROC curve with the minimum distance (d) to sensitivity= 1 and
speciﬁcity= 1)42 was determined using Pythagoras’ theorem:
d ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð1 sensitivityÞ2 þ ð1 specificityÞ2
q
ð2Þ
Individual data points, mean and s.e.m. are displayed in the ﬁgures. Data were
tested for normality, using violation of the Shapiro–Wilk test at p < 0.01 as the
criterion. Data sets not meeting the normality assumption were analyzed using
non-parametric tests (as indicated in the ﬁgure legends).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data used in the preparation of this article were obtained from the Pre-symptomatic
Evaluation of Novel or Experimental Treatments for Alzheimer’s Disease (PREVENT-
AD) program (http://www.prevent-alzheimer.ca) data release 2.0 (30 November 2015,
Update: 07 June 2016). Other relevant data are available directly from the authors.
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